Learn about NICE and NHS England’s subscription-style purchasing model for antimicrobials, its implementation, and its impact on healthcare investment strategies.
Introduction
Antimicrobial resistance (AMR) poses a significant threat to global health, with current estimates attributing around 700,000 deaths annually worldwide. If left unaddressed, this number could surge to 10 million by 2050. The development of new antimicrobials is crucial to combating AMR, yet traditional investment models have struggled to support this vital research. Enter the subscription investment model, an innovative approach adopted by NICE and NHS England in the UK to revolutionize how antimicrobials are evaluated and purchased.
Understanding the Subscription Investment Model
The subscription investment model shifts the traditional pharmaceutical funding paradigm. Instead of companies relying on high-volume sales to recoup their investments, this model offers a fixed annual fee for new antimicrobials. This approach ensures that companies receive a steady income, encouraging sustained investment in antimicrobial research without the pressure of immediate high sales volumes.
Key Features:
- Fixed Annual Fee: Payments are based on the health value of the antimicrobial rather than the quantity used.
- Health Technology Assessment (HTA): Determines the value of antimicrobials to the NHS, ensuring funds are allocated efficiently.
- Delinked Payments: Financial incentives are decoupled from the volume of sales, promoting responsible usage to prevent resistance development.
NICE and NHS England’s Pilot Project
In response to the UK Government’s 2019 national action plan for AMR, NICE and NHS England initiated a pilot project to test the feasibility of the subscription model. This pilot focused on two antimicrobial products:
- Ceftazidime with Avibactam
- Cefiderocol
Pilot Outcomes:
- Global First: July 2022 marked the first-ever subscription-style contracts where payments were decoupled from product volume.
- Commercial Discussions: NICE’s guidance based on HTA informed negotiations between NHS England and the antimicrobial companies involved.
- Sustainable Investment: The model provided a reliable financial framework, making antimicrobial development a more attractive investment.
Implementation of the New Subscription Model (2024)
Building on the pilot’s success, NICE and NHS England unveiled a comprehensive subscription model in May 2024. This model was further rolled out with the first procurement round in August 2024.
Enhancements:
- Antimicrobial Evaluation Panel: Ensures that assessments are thorough and include relevant expertise.
- Contractual Guarantees: Maintains supply while ensuring that payments remain unaffected by usage volumes.
- Public Consultation: Incorporates feedback to refine and optimize the model for broader implementation.
Impact on Healthcare Investment Strategies
The subscription investment model has profound implications for healthcare investment strategies:
- Encourages Innovation: By providing predictable funding, it incentivizes companies to invest in developing new antimicrobials.
- Promotes Sustainability: Ensures that antimicrobial products remain financially viable without over-reliance on sales volumes.
- Enhances Collaboration: Facilitates stronger partnerships between healthcare providers and pharmaceutical companies, aligning goals towards combating AMR.
Future Prospects
The success of the subscription investment model in the UK sets a precedent for other regions grappling with AMR. As this model gains traction, it could reshape global healthcare investment landscapes, fostering a more sustainable and resilient approach to antimicrobial development.
Conclusion
The subscription investment model pioneered by NICE and NHS England represents a transformative approach to antimicrobial funding. By decoupling payments from sales volumes and focusing on the health value, this model not only addresses the urgent challenge of AMR but also paves the way for more sustainable healthcare investment strategies.
Ready to revolutionize your investment approach? Join Oriel IPO today and connect with innovative opportunities in the UK startup ecosystem.
